CD274 and non-small cell lung carcinoma: In recent years, immune checkpoint inhibitors (ICIs) targeting programmed death ligand 1 (PD-L1) have become an important additional cornerstone in the therapy of advanced non-small cell lung cancer (NSCLC) (1–5).